Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38


Peer-review and post-publication discourse: The challenges.

Shrimali RK, Khan YM.

Indian J Cancer. 2019 Nov 18. doi: 10.4103/ijc.IJC_527_18. [Epub ahead of print] No abstract available.


Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance.

Verma V, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, Nandre R, Gaur P, Lopez J, Sade-Feldman M, Yizhak K, Bjorgaard SL, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hammond SA, Tan M, Qi J, Wong P, Merghoub T, Wolchok J, Hacohen N, Janik JE, Mkrtichyan M, Gupta S, Khleif SN.

Nat Immunol. 2019 Nov;20(11):1555. doi: 10.1038/s41590-019-0519-6.


PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance.

Verma V, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, Nandre R, Gaur P, Lopez J, Sade-Feldman M, Yizhak K, Bjorgaard SL, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hammond SA, Tan M, Qi J, Wong P, Merghoub T, Wolchok J, Hacohen N, Janik JE, Mkrtichyan M, Gupta S, Khleif SN.

Nat Immunol. 2019 Sep;20(9):1231-1243. doi: 10.1038/s41590-019-0441-y. Epub 2019 Jul 29. Erratum in: Nat Immunol. 2019 Sep 24;:.


How do clinicians rate patient's performance status using the ECOG performance scale? A mixed-methods exploration of variability in decision-making in oncology.

Datta SS, Ghosal N, Daruvala R, Chakraborty S, Shrimali RK, van Zanten C, Parry J, Agrawal S, Atreya S, Sinha S, Chatterjee S, Gollins S.

Ecancermedicalscience. 2019 Mar 28;13:913. doi: 10.3332/ecancer.2019.913. eCollection 2019.


Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center.

Shrimali RK, Nallathambi C, Saha A, Das A, Prasath S, Mahata A, Arun B, Mallick I, Achari R, Dabkara D, Thambudorai R, Chatterjee S.

Indian J Cancer. 2018 Apr-Jun;55(2):125-133. doi: 10.4103/ijc.IJC_469_17.


Survival Outcomes From Concurrent Chemoradiation for Lung Cancer in Indian Patients are Comparable With Reported UK Outcomes.

Arunsingh M, Shrimali RK, Chakraborty S, Arun B, Prasath S, Chatterjee S.

Clin Oncol (R Coll Radiol). 2019 Apr;31(4):265. doi: 10.1016/j.clon.2018.12.002. Epub 2018 Dec 26. No abstract available.


Impact of modern radiotherapy techniques on survival outcomes for unselected patients with large volume non-small cell lung cancer.

Shrimali RK, Chakraborty S, Prasath S, Arun B, Chatterjee S.

Br J Radiol. 2019 Mar;92(1095):20180928. doi: 10.1259/bjr.20180928. Epub 2018 Nov 29.


Development and validation of a decision support tool to select IMRT as radiotherapy treatment planning modality for patients with locoregionally advanced non-small cell lung cancers (NSCLC).

Shrimali RK, Chakraborty S, Bhattacharyya T, Mallick I, Achari RB, Prasath S, Arun B, Mahata A, Vidhya Shree M, Vishnupriya E, Chatterjee S.

Br J Radiol. 2019 Feb;92(1094):20180431. doi: 10.1259/bjr.20180431. Epub 2018 Nov 9.


Resource requirements and reduction in cardiac mortality from deep inspiration breath hold (DIBH) radiation therapy for left sided breast cancer patients: A prospective service development analysis.

Chatterjee S, Chakraborty S, Moses A, Nallathambi C, Mahata A, Mandal S, Achari RB, Mallick I, Shrimali RK, Bhattacharyya T, Agrawal S, Ghosh J, Ahmed R.

Pract Radiat Oncol. 2018 Nov - Dec;8(6):382-387. doi: 10.1016/j.prro.2018.03.007. Epub 2018 Mar 21.


Actual gains in dosimetry and treatment delivery efficiency from volumetric modulated arc radiotherapy for inoperable, locally advanced lung cancer over five-field forward-planned intensity-modulated radiotherapy.

Shrimali RK, Arunsingh M, Reddy GD, Mandal S, Arun B, Prasath S, Sinha S, Mallick I, Achari R, Chatterjee S.

Indian J Cancer. 2017 Jan-Mar;54(1):155-160. doi: 10.4103/ijc.IJC_79_17.


Continuous hyperfractionated accelerated radiotherapy using modern radiotherapy techniques for nonsmall cell lung cancer patients unsuitable for chemoradiation.

Shrimali RK, Arunsingh M, Das A, Mallick I, Mahata A, Prasath S, Achari R, Chatterjee S.

Indian J Cancer. 2017 Jan-Mar;54(1):120-126. doi: 10.4103/ijc.IJC_158_17.


Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis.

Shrimali RK, Ahmad S, Verma V, Zeng P, Ananth S, Gaur P, Gittelman RM, Yusko E, Sanders C, Robins H, Hammond SA, Janik JE, Mkrtichyan M, Gupta S, Khleif SN.

Cancer Immunol Res. 2017 Sep;5(9):755-766. doi: 10.1158/2326-6066.CIR-17-0292.


High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma.

Achari R, Arunsingh M, Badgami RK, Saha A, Chatterjee S, Shrimali RK, Mallick I, Arun B.

Clin Oncol (R Coll Radiol). 2017 Jun;29(6):335-343. doi: 10.1016/j.clon.2017.01.010. Epub 2017 Feb 8.


Acute toxicity and its dosimetric correlates for high-risk prostate cancer treated with moderately hypofractionated radiotherapy.

Arunsingh M, Mallick I, Prasath S, Arun B, Sarkar S, Shrimali RK, Chatterjee S, Achari R.

Med Dosim. 2017 Spring;42(1):18-23. doi: 10.1016/j.meddos.2016.10.002. Epub 2017 Jan 24.


Outcomes Following a Moderately Hypofractionated Adjuvant Radiation (START B Type) Schedule for Breast Cancer in an Unscreened Non-Caucasian Population.

Chatterjee S, Arunsingh M, Agrawal S, Dabkara D, Mahata A, Arun I, Shrimali RK, Achari R, Mallick I, Ahmed R.

Clin Oncol (R Coll Radiol). 2016 Oct;28(10):e165-72. doi: 10.1016/j.clon.2016.05.008. Epub 2016 Jun 28.


Evaluating the Need for Daily Image Guidance in Head and Neck Cancers Treated with Helical Tomotherapy: A Retrospective Analysis of a Large Number of Daily Imaging-based Corrections.

Saha A, Mallick I, Das P, Shrimali RK, Achari R, Chatterjee S.

Clin Oncol (R Coll Radiol). 2016 Mar;28(3):178-84. doi: 10.1016/j.clon.2015.11.014. Epub 2015 Dec 30.


Pitfalls and Challenges to Consider before Setting up a Lung Cancer Intensity-modulated Radiotherapy Service: A Review of the Reported Clinical Experience.

Shrimali RK, Mahata A, Reddy GD, Franks KN, Chatterjee S.

Clin Oncol (R Coll Radiol). 2016 Mar;28(3):185-97. doi: 10.1016/j.clon.2015.08.002. Epub 2015 Aug 29. Review.


Programmed death-1 & its ligands: promising targets for cancer immunotherapy.

Shrimali RK, Janik JE, Abu-Eid R, Mkrtichyan M, Khleif SN.

Immunotherapy. 2015;7(7):777-92. doi: 10.2217/imt.15.49. Epub 2015 Aug 7. Review.


Docetaxel-induced Haemorrhagic Interstitial Pneumonitis - An Acute Life-threatening Adverse Effect.

Chatterjee S, Pilaka VK, Mukhopadhyay S, Shrimali RK, Ahmed R.

Clin Oncol (R Coll Radiol). 2015 Aug;27(8):483-4. doi: 10.1016/j.clon.2015.03.011. Epub 2015 Apr 22. No abstract available.


Planning target volumes determine weight loss in highly conformal radiation therapy in head and neck cancers--a validation study.

Gupta SK, Mallick I, Ray R, Shrimali RK, Achari R, Chatterjee S.

Clin Oncol (R Coll Radiol). 2014 Oct;26(10):668. doi: 10.1016/j.clon.2014.05.008. Epub 2014 Jun 5. No abstract available.


Malignant struma ovarii: the west of Scotland experience and review of literature with focus on postoperative management.

Shrimali RK, Shaikh G, Reed NS.

J Med Imaging Radiat Oncol. 2012 Aug;56(4):478-82. doi: 10.1111/j.1754-9485.2012.02394.x. Epub 2012 May 28. Review.


Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.

Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA, Feldman SA, Restifo NP, Rosenberg SA.

J Clin Invest. 2010 Nov;120(11):3953-68. doi: 10.1172/JCI43490. Epub 2010 Oct 11.


Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.

Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA.

Cancer Res. 2010 Aug 1;70(15):6171-80. doi: 10.1158/0008-5472.CAN-10-0153. Epub 2010 Jul 14.


Role of selenium-containing proteins in T-cell and macrophage function.

Carlson BA, Yoo MH, Shrimali RK, Irons R, Gladyshev VN, Hatfield DL, Park JM.

Proc Nutr Soc. 2010 Aug;69(3):300-10. doi: 10.1017/S002966511000176X. Epub 2010 Jun 25.


Dose-dense and dose-intense chemotherapy for small cell ovarian cancer: 2 cases and review of literature.

Shrimali RK, Correa PD, Reed NS.

Med Oncol. 2011 Sep;28(3):766-70. doi: 10.1007/s12032-010-9509-0. Epub 2010 Apr 2. Review.


Adjuvant radiotherapy with 50 Gy after limb-sparing surgery for soft-tissue sarcoma--West of Scotland experience.

Shrimali RK, Correa PD, Lee KC, Lai CN, Kakumanu SA, Cowie F.

Clin Oncol (R Coll Radiol). 2010 May;22(4):322-3. doi: 10.1016/j.clon.2010.02.009. Epub 2010 Mar 19. No abstract available.


Positron emission tomography with computed tomography (PET-CT) to evaluate the response of bone metastases to non-surgical treatment.

Correa PD, Shrimali RK, Han S, Rizwanullah M.

BMJ Case Rep. 2010 May 6;2010. pii: bcr1120092457. doi: 10.1136/bcr.11.2009.2457.


Trastuzumab-induced radiation recall dermatitis--first reported case.

Shrimali RK, McPhail NJ, Correa PD, Fraser J, Rizwanullah M.

Clin Oncol (R Coll Radiol). 2009 Oct;21(8):634-5. doi: 10.1016/j.clon.2009.03.003. Epub 2009 Apr 15. No abstract available.


The selenocysteine tRNA STAF-binding region is essential for adequate selenocysteine tRNA status, selenoprotein expression and early age survival of mice.

Carlson BA, Schweizer U, Perella C, Shrimali RK, Feigenbaum L, Shen L, Speransky S, Floss T, Jeong SJ, Watts J, Hoffmann V, Combs GF, Gladyshev VN, Hatfield DL.

Biochem J. 2009 Feb 15;418(1):61-71. doi: 10.1042/BJ20081304.


Selenoproteins mediate T cell immunity through an antioxidant mechanism.

Shrimali RK, Irons RD, Carlson BA, Sano Y, Gladyshev VN, Park JM, Hatfield DL.

J Biol Chem. 2008 Jul 18;283(29):20181-5. doi: 10.1074/jbc.M802559200. Epub 2008 May 16.


Low-dose palliative splenic irradiation in haematolymphoid malignancy.

Shrimali RK, Correa PD, O'Rourke N.

J Med Imaging Radiat Oncol. 2008 Jun;52(3):297-302. doi: 10.1111/j.1440-1673.2008.01958.x.


Valuable lessons from treatment of non-small cell lung cancer with erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.

Shrimali RK, Correa PD, Rizwanullah M.

BMJ Case Rep. 2008;2008:bcr0620080075. doi: 10.1136/bcr.06.2008.0075. Epub 2008 Nov 20. No abstract available.


Selenoprotein expression is essential in endothelial cell development and cardiac muscle function.

Shrimali RK, Weaver JA, Miller GF, Starost MF, Carlson BA, Novoselov SV, Kumaraswamy E, Gladyshev VN, Hatfield DL.

Neuromuscul Disord. 2007 Feb;17(2):135-42. Epub 2006 Dec 4.


Selenocysteine tRNA identification in the model organisms Dictyostelium discoideum and Tetrahymena thermophila.

Shrimali RK, Lobanov AV, Xu XM, Rao M, Carlson BA, Mahadeo DC, Parent CA, Gladyshev VN, Hatfield DL.

Biochem Biophys Res Commun. 2005 Apr 1;329(1):147-51.


Sonographically guided core biopsy in the assessment of thyroid nodules.

Harvey JN, Parker D, De P, Shrimali RK, Otter M.

J Clin Ultrasound. 2005 Feb;33(2):57-62.


An unusual endocrine cause of hyponatraemia.

De P, Shrimali RK, Subramonian S, Child DF.

Postgrad Med J. 2002 Jul;78(921):433, 437-8. No abstract available.


Integrins and disintegrins: the candidate molecular players in sperm-egg interaction.

Shrimali RK, Reddy KV.

Indian J Exp Biol. 2000 May;38(5):415-24. Review.


Supplemental Content

Loading ...
Support Center